Lupus science & medicine · 2026
Elevated serum brain injury markers are associated with disease activity, pro-inflammatory cytokine levels and cognitive dysfunction in adolescents with childhood-onset SLE.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mwizerwa Oscar, Ledochowski Justine, Ramanathan Ganesh, Tal Tala E, Mossad Sarah I, Zapparoli Busi, Ng Lawrence, Jeyanathan Asha, Davis Adrienne, Hiraki Linda T, Levy Deborah M, Wither Joan, Touma Zahi, Danguecan Ashley, Yeh Anne, Knight Andrea M
Аннотация
OBJECTIVE: This study examined serum brain injury markers and their associations with disease features, cytokines associated with microglial activation in lupus and cognitive dysfunction (CD) in adolescents with childhood-onset SLE (cSLE).
METHODS: We used cross-sectional data from cSLE patients (aged 12-17 years) and age-matched, sex-matched healthy controls. Serum levels of brain injury markers (serum neurofilament light, glial fibrillar acidic protein (GFAP), Tau), interferon (IFN)-α, IFN-γ and interleukin-6 (IL-6) were quantified using Simoa assays. cSLE features included disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000), damage (Systemic Lupus International Collaborating Clinics damage index) and glucocorticoid (GC) exposure. A neurocognitive battery assessed executive function, attention and working memory, and CD was determined using standardised scores. We compared brain injury marker levels between cSLE and controls, and those with and without CD using Wilcoxon rank-sum tests. We calculated correlations between injury markers, disease features and cytokines and examined differences in disease features between those with and without high-level brain injury markers (>90th percentile) (using Bonferroni correction).
RESULTS: Participants included 56 cSLE patients (median disease duration=10.6 months (IQR 2.0-14.1), one with neuropsychiatric lupus) and 43 controls. Levels were higher in cSLE versus controls for GFAP (z=-3.97, p<0.001), Tau (z=-2.10, p=0.035), IFN-α (z=-4.80, p<0.001), IFN-γ (z=-2.42, p=0.015) and IL-6 (-3.09, p=0.002). Severe CD (≥2 SD from standardised mean) was present in 31% cSLE versus 9% controls (chi2=6.69, p=0.01), associated with higher Tau levels for cSLE (z=-3.94, p<0.001). High-level brain injury markers were observed in 13 (23%) cSLE patients associated with higher SLEDAI-2K, IL-6 levels and current GC dose.
CONCLUSION: Brain injury marker levels were high and associated with disease activity and CD in this cSLE adolescent cohort, suggesting a link between systemic inflammation and clinically under-detected neuronal/glial injury. Larger, longitudinal studies should explore the potential clinical utility of brain injury markers for clinical assessment of brain involvement in cSLE.
METHODS: We used cross-sectional data from cSLE patients (aged 12-17 years) and age-matched, sex-matched healthy controls. Serum levels of brain injury markers (serum neurofilament light, glial fibrillar acidic protein (GFAP), Tau), interferon (IFN)-α, IFN-γ and interleukin-6 (IL-6) were quantified using Simoa assays. cSLE features included disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000), damage (Systemic Lupus International Collaborating Clinics damage index) and glucocorticoid (GC) exposure. A neurocognitive battery assessed executive function, attention and working memory, and CD was determined using standardised scores. We compared brain injury marker levels between cSLE and controls, and those with and without CD using Wilcoxon rank-sum tests. We calculated correlations between injury markers, disease features and cytokines and examined differences in disease features between those with and without high-level brain injury markers (>90th percentile) (using Bonferroni correction).
RESULTS: Participants included 56 cSLE patients (median disease duration=10.6 months (IQR 2.0-14.1), one with neuropsychiatric lupus) and 43 controls. Levels were higher in cSLE versus controls for GFAP (z=-3.97, p<0.001), Tau (z=-2.10, p=0.035), IFN-α (z=-4.80, p<0.001), IFN-γ (z=-2.42, p=0.015) and IL-6 (-3.09, p=0.002). Severe CD (≥2 SD from standardised mean) was present in 31% cSLE versus 9% controls (chi2=6.69, p=0.01), associated with higher Tau levels for cSLE (z=-3.94, p<0.001). High-level brain injury markers were observed in 13 (23%) cSLE patients associated with higher SLEDAI-2K, IL-6 levels and current GC dose.
CONCLUSION: Brain injury marker levels were high and associated with disease activity and CD in this cSLE adolescent cohort, suggesting a link between systemic inflammation and clinically under-detected neuronal/glial injury. Larger, longitudinal studies should explore the potential clinical utility of brain injury markers for clinical assessment of brain involvement in cSLE.
Предметные рубрики MeSH
HumansAdolescentFemaleMaleChildBiomarkersCross-Sectional StudiesInterleukin-6Lupus Erythematosus, SystemicCognitive DysfunctionCytokinesGlial Fibrillary Acidic Proteintau ProteinsInterferon-gammaBrain InjuriesNeurofilament ProteinsCase-Control StudiesInterferon-alphaSeverity of Illness IndexAge of Onset